// App-Quantinova.ai

e16555 : Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).

Researchers

Presenter

  • Ignacio Duran

Principal Investigators

  • Luis Costa

  • Javier Puente

  • Urbano Anido

  • Lidia Martin

  • Jessica Gomez

  • Daniel Castellano

Medical Centers

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Centro Hospitalar de Lisboa Norte, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

  • Hospital Universitario Clinico de Santiago, Santiago de Compostela, Spain

  • Amgen, Barcelona, Spain

  • Anaxomics Biotech, Barcelona, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

Locations

  • Spain

  • Portugal

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved